PATENT CLAIM ANALYSIS

Application Number: 15942321
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "210020"]

Abstract:
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Claim (Index 15):
The compound of  claim 14 , wherein A is (C 3-7  cycloalkyl)(C 1-6  alkyl) j -, (C 2-9  heterocyclyl)(C 1-6  alkyl) j -, (C 6-10  aryl) q\u2032 -(C 1-6  alkyl) n -O\u2014, or (C 2-7  heterocyclyl)-O\u2014, wherein said cycloalkyl, alkyl, aryl or heterocyclyl can be optionally substituted; j is 1 or 0; and n is 1 or 0 and q\u2032 is 1 or 0, provided that one of n and q\u2032 is 1.

Metadata:
- Claim Count in Document: 140.0
- Percentile: 90.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12530648', '13102720', '15281923', '13266976', '15852639']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7595274798193483
- 35 USC 102 Novelty (BERT): 0.5150317581813634
- Combined Prediction Score: 0.7350779076555498
- Mean Citation Score: 269.39763800000003
- Max Citation Score: 276.27457000000004
- Similarity Product: 203.8163421874154

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test